TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06083233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventriculo-peritoneal shunt placement
Description: Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prechamber puncture
Description: Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of cerebrospinal fluid (5 days, 1 month a 2 months after surgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #1
Description: Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours prior surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #1
Description: Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours prior surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #2
Description: Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #3
Description: Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 5 days after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #4 and #5
Description: Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
Study: NCT06318403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Description: All patients will receive patches with identical labeling from our pharmacy, to be applied twice weekly. In the study group, these will contain 0.025 mg/day of estradiol. In the control group, these will be placebo. These will be applied twice weekly for three months beginning at the time of surgery and extending for three months after surgery.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rotator Cuff Repair Surgery
Description: The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator Cuff Repair Surgery
Description: The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
Study: NCT05254002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862 ) 10 mg
Description: oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862 ) 10 mg
Description: oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: oral administration, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: oral administration, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin Placebo
Description: Matching placebo to empagliflozin oral administration, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862 ) 20 mg
Description: oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862 ) 20 mg
Description: oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone Placebo
Description: Matching Placebo to Finerenone oral administration once daily
Study: NCT06246916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fianlimab
Description: Intravenous (IV) administration every 3 weeks (Q3W) in combination with cemiplimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: IV administration Q3W in combination with fianlimab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: relatlimab+nivolumab
Description: IV administration every 4 weeks (Q4W)
Study: NCT06137170

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Follow clinical administration.

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Follow clinical administration.
Study: NCT05926414

Intervention type: DRUG
Intervention: Enavogliflozin
Description: treated with Envlo tab. 0.3mg

Intervention type: DRUG
Intervention: Enavogliflozin
Description: Envlomet SR Tablet 0.3/1,000mg
Study: NCT06633900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM naltrexone
Description: The study drug is an intramuscular injection of naltrexone (380mg), administered every 4 weeks via an injection in the ventrogluteal region.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants assigned to usual care will receive a harm reduction bundle in clinic. It will include the following components: 1) intranasal naloxone 4mg x 2, 2) participant choice of safer consumption kits based on substances and route used (specific materials for inhaled use vs. injecting, based on common use practices in the region), 3) fentanyl test kits with 2 lateral flow assays per package along with instructions to minimize false positive results, and 4) information about universal overdose precautions (behavioral modifications to optimize safety like using in the presence of others, use a test dose of new substances, etc.)
Study: NCT04564898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days~Part 2~• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Part 1 • Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days~Part 2~• Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days~Part 2~• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days
Study: NCT05440643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut SLIT-tablet
Description: Peanut extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut SLIT-tablet
Description: Peanut extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut SLIT-tablet
Description: Peanut extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut SLIT-tablet
Description: Peanut extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut SLIT-tablet
Description: Peanut extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut SLIT-tablet
Description: Peanut extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut SLIT-tablet
Description: Peanut extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut SLIT-tablet
Description: Peanut extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut SLIT-tablet
Description: Peanut extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut SLIT-tablet
Description: Peanut extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut SLIT-tablet
Description: Peanut extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut SLIT-tablet
Description: Peanut extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05704361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7121932 IV - SAD
Description: Part 1: Participants will receive a single dose of RO7121932 administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7121932 SC - SAD
Description: Part 2: Participants will receive a single dose of RO7121932 administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7121932 - MAD
Description: Part 3: Participants will receive multiple doses of RO7121932 administered as SC injections.
Study: NCT06286670

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single Implant Fixation
Description: Single implant fixation with either a precontoured lateral locking plate or an intramedullary nail.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dual Implant Fixation
Description: Dual implant fixation with either a lateral locking plate plus an intramedullary nail or a lateral locking plate plus a supplemental medial plate.
Study: NCT04827563

Intervention type: DEVICE
Intervention: EndoPAT
Description: An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.

Intervention type: DEVICE
Intervention: EndoPAT
Description: An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.

Intervention type: DEVICE
Intervention: Blood Pressure Cuff
Description: A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.

Intervention type: DEVICE
Intervention: Blood Pressure Cuff
Description: A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: A test used to conduct an ultrasound of participant's heart.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: A test used to conduct an ultrasound of participant's heart.

Intervention type: OTHER
Intervention: Quality of Life Assessment
Description: A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.

Intervention type: OTHER
Intervention: Quality of Life Assessment
Description: A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.

Intervention type: OTHER
Intervention: Blood Tests
Description: Routinely collected for all participants who begin carfilzomib treatment.

Intervention type: OTHER
Intervention: Blood Tests
Description: Routinely collected for all participants who begin carfilzomib treatment.
Study: NCT04804644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Brain Radiotherapy
Description: Undergo HA-WBRT
Study: NCT06428903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189 tablet
Description: ADC189 tablet, 45 mg, single oral dose in each Group. (Part 1 study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189 tablet
Description: ADC189 tablet, 45 mg, single oral dose in each Group. (Part 1 study)
Study: NCT05223816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG161
Description: Name: VG161 (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) Concentration/Content: ≥1×107 PFU/mL; 1.0 mL/vial. Actual titer will be recorded on Certificate of Analysis.~Composition: VG161,50 mM Tris-HCl, 150mM NaCl, \<5% glycerol Route of Administration: Intratumoral injection or image guided intratumoral injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG161
Description: Name: VG161 (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) Concentration/Content: ≥1×107 PFU/mL; 1.0 mL/vial. Actual titer will be recorded on Certificate of Analysis.~Composition: VG161,50 mM Tris-HCl, 150mM NaCl, \<5% glycerol Route of Administration: Intratumoral injection or image guided intratumoral injections.
Study: NCT06428903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189 granules
Description: ADC189 granules, 45 mg, single oral dose in each Group. (Part 1 study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189 granules
Description: ADC189 granules, 45 mg, single oral dose in each Group. (Part 1 study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189 180mg
Description: ADC189 tablet, 180 mg, single oral dose. (Part 2 study)
Study: NCT04998604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: solution for injection subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: solution for injection subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: solution for injection subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: solution for injection subcutaneous
Study: NCT06628362

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be volume-matched and administered subcutaneously (SC) once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
Study: NCT06364371

Intervention type: OTHER
Intervention: Medical examination
Description: Eligible patients will be prospectively enrolled, and images of their pre-neoadjuvant treatment, during-treatment, and post-treatment preoperative magnetic resonance imaging (MRI) scans, histopathology slides stained with hematoxylin and eosin (H\&E), carcinoembryonic antigen (CEA), and circulating tumor DNA (ctDNA) will be collected and annotated.
Study: NCT05361993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Aripiprazole
Description: Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biofeedback
Description: Biofeedback therapy Biofeedback therapy, three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training（using the Infiniti3000A biofeedback system，Thought Technology Ltd.）.Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.
Study: NCT05951777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous HB-adMSCs
Description: Hope Biosciences autologous adipose-derived mesenchymal stem cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sterile Saline Solution 0.9%
Study: NCT05671406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensor-controlled digital game
Description: The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid hospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal Hypertension health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback to motivate engagement in and generate habit formation of heart failure related self-management behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensor only
Description: Real-time behaviors of physical activity will be tracked by an off-the-shelf sensor and app (Withings). This group will also be provided with standardized evidence-based Hypertension educational material. However, the data from the Withings sensor will not be routed to the SCDG.
Study: NCT06101745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nizaracianine Triflutate
Description: Participants will receive up to 3 intravenous bolus injections with a minimal interval between doses of 60 minutes (surgeon discretion). Dose will be 1.0, 2.5 or 5.0mg depending on trial phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: In Phase 3A only, 50 subjects will be randomly allocated to receive sugar placebo
Study: NCT06085872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REThink Life Game
Description: REThink Life Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of four levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change and positive bias.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PsyPills
Description: PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress. The efficacy of the app adjunct to other therapeutic tools within the platform in our projects will be tested.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PsyPills
Description: PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress. The efficacy of the app adjunct to other therapeutic tools within the platform in our projects will be tested.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MoodWheel
Description: Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
Study: NCT03714711

Intervention type: PROCEDURE
Intervention: total hip arthroplasty
Description: Total hip replacement

Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: Total knee replacement